Transaction

* In one of the most significant oncology licensing deals of 2025 to date, Pfizer has secured global rights (excluding mainland China) to 3SBio's promising PD-1/VEGF bispecific antibody, SSGJ-707, for a

PUBLICATION_TIME(BEIJING): 2025-03-24 18:02:10 PROVIDER: Novo Nordisk A/S HEADLINE: The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist SUB_